Home・Aandelen Lijst・Novo Nordisk A-S (Class B)

Novo Nordisk A-S (Class B)

Gesloten

299.25 -0.86

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

296.85

Max

299.8

Belangrijke statistieken
By Trading Economics
Inkomsten	-28B 21B
Verkoop	-18B 78B
K/W Sectorgemiddelde	11.141 56.659
EPS	6.18
Dividendrendement	4
Winstmarge	26.742
Werknemers	66,700
EBITDA	-31B 39B

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+9.53% upside

Dividenden
By Acuity
Dividendrendement Sectorgemiddelde	4.00% 2.18%
Volgende Winsten	4 nov 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-72B 1.3T
Vorige openingsprijs	300.11
Vorige sluitingsprijs	299.25

Novo Nordisk A-S (Class B) Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

5 sep 2026, 23:51 UTC

Core PPI Release on September 10 Expected to Show 0.3% Increase Amid Strong Employment Data and Speculation of Fed Rate Hikes Due to Inflation Concerns.

5 sep 2026, 23:41 UTC

U.S. Producer Price Inflation Expected to Rise 0.3% in August Amid Strong Job Growth and Heightened Interest Rate Hike Speculation

5 sep 2026, 23:31 UTC

Euro Area's Deposit Facility Rate Expected to Rise to 0.025% Amid ECB Tightening and Investor Caution Ahead of September Release

5 sep 2026, 23:01 UTC

Australia's Consumer Confidence Set for Release Amid Mixed Economic Signals and Global Uncertainties

5 sep 2026, 22:51 UTC

Mexico's Inflation Rate Release on September 9, 2026, Sparks Market Concerns Amid Strong U.S. Jobs Data and Potential Interest Rate Adjustments.

5 sep 2026, 22:51 UTC

Mexico's August 2026 Inflation Rate Release Expected to Influence Monetary Policy and Investor Confidence Amid Easing Trends.

5 sep 2026, 22:51 UTC

Australia's Westpac Consumer Confidence Index set for release on September 8, amid positive market trends and strong U.S. job growth influencing economic outlook.

5 sep 2026, 22:41 UTC

U.S. MBA 30-Year Mortgage Rate Set to Rise Amid Strong Job Growth and Inflation Concerns, Influencing Fed Interest Rate Expectations

5 sep 2026, 22:31 UTC

Brazil's Central Bank readout on interest rates set for September 8, 2026, amid global economic influences and heightened speculation in financial markets.

5 sep 2026, 22:21 UTC

Japan's Q2 2026 GDP Growth Forecast at 1.1% Amid Concerns Over Sharp Decline in Household Spending

5 sep 2026, 22:21 UTC

Japan's Q2 2026 GDP Growth Rate Release Expected at 0.4% Amid Mixed Economic Signals and Volatile Markets

5 sep 2026, 22:11 UTC

Turkey's TCMB Expected to Maintain 37% Interest Rate Amid Inflation Concerns and Global Market Influences Ahead of September Decision.

5 sep 2026, 22:11 UTC

UK Housing Market Sentiment Remains Negative as RICS House Price Balance Forecasts Slight Improvement Amid Broader Economic Concerns

5 sep 2026, 21:51 UTC

South Korea's Unemployment Rate Release on September 8, 2026, Expected Amid Global Job Growth Optimism Following Strong U.S. Data

5 sep 2026, 21:31 UTC

Cautious Market Sentiment Ahead of BRC Retail Sales Monitor YoY Release, Forecasting 1.2% Growth Amid Mixed Economic Signals

5 sep 2026, 21:21 UTC

Spain's Consumer Confidence Index set for release on September 8, with analysts hopeful for improvement amid geopolitical tensions and inflation concerns.

5 sep 2026, 21:21 UTC

South Africa's Q2 2026 GDP Growth Rate Release on September 8 Sparks Cautious Optimism Amid Global Economic Trends.

5 sep 2026, 21:21 UTC

South Africa's Q2 2026 GDP Growth Rate Release on September 8 Sparks Cautious Optimism Amid Global Economic Recovery Signals.

5 sep 2026, 20:41 UTC

Japan's Current Account Surplus Forecasted at JPY 2,870 Billion Amid Cautious Sentiment from Declining Household Spending

5 sep 2026, 19:21 UTC

API Crude Oil Stock Change Data Release on September 9, 2026, Anticipated Amid Geopolitical Tensions and Recent Inventory Volatility.

5 sep 2026, 19:11 UTC

Italy's Industrial Production MoM data for July 2026 set to release on September 10, with a forecasted increase of only 0.3% amid declining trends and mixed signals from Europe.

5 sep 2026, 19:01 UTC

Correlated Moves

Cardano is rising during Saturday's session, supported by Ethereum's performance. The asset is trading above its 20-day moving average, reflecting strong momentum.

5 sep 2026, 18:31 UTC

Swiss Consumer Confidence Index Expected to Remain Low at -32.0 Amidst Cautious Market Sentiment and Global Economic Concerns

5 sep 2026, 18:11 UTC

EUR/SEK is trading roughly flat in after-market hours, showing little change since Friday's close and remaining near the upper end of its one-month range.

5 sep 2026, 18:11 UTC

EUR/CAD is trading roughly flat in after-market hours, showing little change from Friday's close and remaining near the lower end of its one-month range.

5 sep 2026, 18:11 UTC

Turkey's Industrial Production YoY data release on September 10, 2026, may reflect cautious optimism amid recent fluctuations and mixed market sentiment.

5 sep 2026, 17:41 UTC

U.S. Monthly Budget Statement on September 11, 2026, expected to reveal rising deficits amid cautious fiscal sentiment and potential Fed interest rate decisions.

5 sep 2026, 17:41 UTC

France's Industrial Production Expected to Rise 0.3% Amid Cautious Economic Sentiment and Construction Sector Decline

5 sep 2026, 17:31 UTC

UK's Non-EU Goods Trade Balance Report Set for Release on September 11, 2026 Amidst Stable Market Sentiment.

5 sep 2026, 17:31 UTC

UK Monthly GDP Expected to Remain Flat at 0.0% for July Amid Cautious Investor Sentiment and Mixed Economic Signals

Peer Vergelijking

Prijswijziging

Novo Nordisk A-S (Class B) Prognose

Koersdoel

By TipRanks

9.53% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,162.73 DKK 9.53%

Hoogste 1,550 DKK

Laagste 720 DKK

Gebaseerd op 11 Wall Street-analisten die 12-maands prijsdoelen bieden voor Novo Nordisk A-S (Class B) - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

11 ratings

Buy

Hold

Sell

Gebaseerd op 11 analisten die aandelenratings hebben gegeven aan Novo Nordisk A-S (Class B) - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Novo Nordisk A-S (Class B)

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.